Long-term survival in patients with refractory angina
Open Access
- 12 May 2013
- journal article
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 34 (34) , 2683-2688
Abstract
Aims An increasing number of patients with severe coronary artery disease (CAD) are not candidates for traditional revascularization and experience angina in spite of excellent medical therapy. Despite limited data regarding the natural history and predictors of adverse outcome, these patients have been considered at high risk for early mortality. Methods and results The OPtions In Myocardial Ischemic Syndrome Therapy (OPTIMIST) program at the Minneapolis Heart Institute offers traditional and investigational therapies for patients with refractory angina. A prospective clinical database includes detailed baseline and yearly follow-up information. Death status and cause were determined using the Social Security Death Index, clinical data, and death certificates. Time to death was analysed using survival analysis methods. For 1200 patients, the mean age was 63.5 years (77.5% male) with 72.4% having prior coronary artery bypass grafting, 74.4% prior percutaneous coronary intervention, 72.6% prior myocardial infarction, 78.3% 3-vessel CAD, 23.0% moderate-to-severe left-ventricular (LV) dysfunction, and 32.6% congestive heart failure (CHF). Overall, 241 patients died (20.1%: 71.8% cardiovascular) during a median follow-up 5.1 years (range 0–16, 14.7% over 9). By Kaplan–Meier analysis, mortality was 3.9% (95% CI 2.8–5.0) at 1 year and 28.4% (95% CI 24.9–32.0) at 9 years. Multivariate predictors of all-cause mortality were baseline age, diabetes, angina class, chronic kidney disease, LV dysfunction, and CHF. Conclusion Long-term mortality in patients with refractory angina is lower than previously reported. Therapeutic options for this distinct and growing group of patients should focus on angina relief and improved quality of life.Keywords
This publication has 43 references indexed in Scilit:
- Intramyocardial, Autologous CD34+ Cell Therapy for Refractory AnginaCirculation Research, 2011
- Clinical and research issues regarding chronic advanced coronary artery disease Part II: Trial design, outcomes, and regulatory issuesAmerican Heart Journal, 2008
- Clinical and research issues regarding chronic advanced coronary artery diseaseAmerican Heart Journal, 2008
- Effects of Ad5FGF-4 in Patients With AnginaJACC, 2007
- Antianginal Efficacy of Ranolazine When Added to Treatment With AmlodipineJACC, 2006
- Direct intramyocardial plasmid vascular endothelial growth factor-A165gene therapy in patients with stable severe angina pectorisJACC, 2005
- The VIVA TrialCirculation, 2003
- The problem of chronic refractory angina. Report from the ESC Joint Study Group on the Treatment of Refractory AnginaEuropean Heart Journal, 2002
- Pharmacological Treatment of Coronary Artery Disease With Recombinant Fibroblast Growth Factor-2Circulation, 2002
- The multicenter study of enhanced external counterpulsation (MUST-EECP): effect of EECP on exercise-induced myocardial ischemia and anginal episodesJACC, 1999